Exelixis | EXEL - Ebit


Exelixis reported $251.34M in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Amgen USD 4.61B 777M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bayer EUR 3.53B 2.42B Mar/2026
BioMarin Pharmaceutical USD 129.65M 68.74M Mar/2026
Bristol-Myers Squibb USD 299M 3.26B Jun/2026
Cytokinetics USD -181.23M 2.86M Mar/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 251.34M 15.43M Mar/2026
Genmab DKK 260M 199M Dec/2025
Glaxosmithkline GBP 2.31B 14.92M Mar/2026
Incyte USD 700.4M 356.23M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
MacroGenics USD -31.88M 19.79M Mar/2026
Merck USD 840M 2.72B Jun/2026
Moderna USD -815M 573M Jun/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Novartis USD 4.73B 549M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
Puma Biotechnology USD -2.2M 11.41M Jun/2024
Sanofi EUR 2.18B 1.56B Mar/2026
Takeda JPY 201.42B 215.04B Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Xencor USD -77.86M 24.23M Mar/2026